industries

Japan’s pharmaceutical market is the third largest globally:

• USA: US$ 425 billion (2020)
• Europa: US$ 200 billion (2020)
• Japan: US$ 150 billion (2020)

The 10 largest (by annual sales) Japanese pharmaceutical companies are

1. Chugai (Hoffmann-La Roche holds 61.16% of shares excluding treasury stock, 59.89% of outstanding shares) sales US$ 5.2 billion (2022)
2. Takeda US$ 5 billion
3. Eisai US$ 4 billion
4. Astellas US$ 3.8 billion
5. Otsuka Holdings US$ 3.6 billion
6. Daiichi Sankyo US$ 3.2 billion
7. Mitsubishi Tanabe Pharma (absorbed by Mitsubishi Chemical) US$ 2.7 billion
8. Sawai Pharmaceutical US$ 2 billion
9. Kyowa Hakko Kirin US$ 1.8 billion
10. Shionogi US$ 1.6 billion

We have about 110 Japanese pharmaceutical companies, and 230 other relevant companies in our business platform.

Japan’s health industries and pharma industries are among the worlds second or third largest, and are in transformation. Japan is in a transformation to open up pharmaceutical and health industry markets with the aim to reduce the therapy gap, ie bring more global therapies to Japanese patients, and to grow the pharmaceutical research and industry platform in Japan.

These transformations create very interesting opportunities for foreign pharmaceutical companies and ventures.

Japanese pharmaceutical companies invest much in foreign pharma ventures, and are also steadily acquiring major foreign established pharma companies.

Regulatory approval systems are being reformed to accelerate approval and to narrow the approval gap.

We have worked with a European pharma multinational on the acquisition of a Japanese pharmaceutical company/factory near Tokyo, and for several years are working with a European regenerative medicine venture developing cell therapies for immune system diseases. We are in preparations with a number of pharmaceutical ventures on their Japan business.

more: https://www.japanstrategy.com/pharma-industry/

Japan’s medical device / MedTech market is the world’s second largest with an estimated market size around US$ 25 billion (2017) and growing between 1% – 2% per year. About 50% of medical devices are imported into Japan from foreign manufacturers including Johnson & Johnson, Medtronic, Siemens and GE.

Japan’s digital device and service market for healthcare is estimated to be around US$ 1.5 by 2025, approx. 75% for prevention, health management and rehabilitation and about 25% for diagnosis and treatment.

Major Japanese medical device manufacturers include:

1. Olympus Medical Systems (revenues approx US$ 5 billion)
2. Hitachi Healthcare (revenues approx US$ 5 billion)
3. Teruo (revenues approx US$ 5 billion)
4. Canon (revenues approx US$ 4 billion)
5. Fujifilm (revenues approx US$ 4 billion)
6. Nipro (revenues approx US$ 3 billion)
7. Hoya, Pentax Medical (revenues approx US$ 3 billion)
8. Sysmex (revenues approx US$ 2 billion)
9. Nihon Koden (revenues approx US$ 1.5 billion)
10. Teijin (revenues approx US$ 1.3 billion)

more: https://www.japanstrategy.com/medical-devices/

xxx

xxx

more: https://www.japanstrategy.com/financial-industry/

xxx

xxx

more: https://www.japanstrategy.com/saas/

xxx

xxx